Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Vehicle-controlled, Study to Evaluate Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)

Next Previous
Trial Profile

A Single-center, Vehicle-controlled, Study to Evaluate Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZR-MD-001 (Primary)
  • Indications Dry eyes; Meibomian gland dysfunction
  • Focus Registrational; Therapeutic Use
  • Sponsors Azura Ophthalmics

Most Recent Events

  • 07 Jan 2021 Status changed from not yet recruiting to completed.
  • 22 Oct 2020 According to an Azura Ophthalmics media release, based on interactions with the U.S. Food and Drug Administration (FDA), company plans to proceed to registration studies in 2021.
  • 07 Jul 2020 Planned initiation date changed from 2 Jun 2020 to 14 Jul 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top